Abstracts tagged "Autoantibodies and inflammatory myositis"

Abstract Number: 2588 • 2019 ACR/ARP Annual Meeting
Myositis-specific and -associated Antibodies in Systemic Sclerosis: Prevalence and Clinical Associations
Amélie Leurs ¹, Sylvain Dubucquoi ¹, François Machuron ¹, Maité Balden ¹, Florence Renaud ¹, Stéphanie Rogeau ¹, Benjamin Lopez ², Marc LAMBERT ³, Sandrine Morell-Dubois ⁴, Hélène Maillard ⁴, Hélène Behal ¹, Eric Hachulla ⁵, David Launay ¹ and Vincent Sobanski¹, ¹CHU Lille, Lille, France, ²Institute of Immunology, CHU Lille, University of Lille, Lille, France, ³Lille University Hospital, Lille, France, ⁴Department of Internal Medicine and Clinical Immunology, CHU Lille, University of Lille, Lille, France, ⁵Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France
Background/Purpose: In systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIM), auto-antibodies are used in daily practice as potent biomarkers of clinical phenotypes. This study aimed…
Abstract Number: 383 • 2018 ACR/ARHP Annual Meeting
Myositis Patients with Anti-U1-RNP and Anti-Ro52 Autoantibodies Are at Risk of Pericarditis, Glomerulonephritis, and Pulmonary Hypertension
Maria Casal-Dominguez¹, Iago Pinal-Fernandez², Andrea Corse³, Julie J. Paik², Jemima Albayda², Livia Casciola-Rosen⁴, Cheilonda Johnson⁵, Sonye K. Danoff⁶, Lisa Christopher-Stine⁶, Eleni Tiniakou⁴ and Andrew Mammen⁷, ¹Muscle Diseases Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health, Bethesda, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Neurology, Johns Hopkins University, Baltimore, MD, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Medicine/Pulmonology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: To define the clinical phenotype of myositis patients with anti-U1- ribonucleoprotein (RNP) autoantibodies. Methods: The clinical features of 20 anti-U1RNP-positive patients were assessed and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].